Novartis Poised To Be First To Market With IL-17 Blocker For Psoriasis

The Swiss drug maker filed its IL-17 inhibitor secukinumab in the U.S. and Europe, providing an opportunity to beat rivals Amgen and Eli Lilly to the market with a first-in-class drug. Secukinumab is one of two drugs Novartis filed in the fourth quarter, the firm reported during a year-end earnings call Jan. 29.